TransCode Therapeutics, Inc.
RNAZNASDAQHealthcare● Active
$5.09
$-0.51(-9.11%)
Market Cap$4837032
P/E Ratio—
52W High$20.99
52W Low$3.82
TransCode Therapeutics, Inc. (RNAZ) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
RNAZ · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 15, 2026EPS Actual
-$21.28
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 15, 2026
After Market Close
RNAZ reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.09
Rev. $41.31B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.09
Rev. Est.$41.31B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 18, 2026 | — | — | — | — | — | — |
| — Q2 FY2026 | May 15, 2026 | — | -$21.28 | — | — | — | — |
| ▼ Q2 FY2026 | Apr 15, 2026 | -$10.08 | -$16.42 | -62.9% | — | — | — |
| ▲ Q4 FY2025 | Nov 14, 2025 | -$9.24 | -$5.49 | +40.6% | — | — | — |
| ▲ Q3 FY2025 | Aug 14, 2025 | -$8.68 | -$4.94 | +43.1% | — | — | — |
| ▼ Q2 FY2025 | May 14, 2025 | -$3.21 | -$16.81 | -423.7% | — | $0.00B | — |
| ▲ Q1 FY2025 | Mar 28, 2025 | -$105.93 | -$16.61 | +84.3% | — | $0.00B | — |
| ▲ Q4 FY2024 | Nov 14, 2024 | -$16.17 | -$5.28 | +67.3% | — | $0.00B | — |
Q3 FY2026
Aug 18, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 15, 2026
EPS Actual
-$21.28
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 15, 2026Miss
EPS Actual
-$16.42
EPS Est.
-$10.08
EPS Surpr.
-62.9%
Revenue
—
Q4 FY2025
Nov 14, 2025Beat
EPS Actual
-$5.49
EPS Est.
-$9.24
EPS Surpr.
+40.6%
Revenue
—
Q3 FY2025
Aug 14, 2025Beat
EPS Actual
-$4.94
EPS Est.
-$8.68
EPS Surpr.
+43.1%
Revenue
—
Q2 FY2025
May 14, 2025Miss
EPS Actual
-$16.81
EPS Est.
-$3.21
EPS Surpr.
-423.7%
Revenue
—
Q1 FY2025
Mar 28, 2025Beat
EPS Actual
-$16.61
EPS Est.
-$105.93
EPS Surpr.
+84.3%
Revenue
—
Q4 FY2024
Nov 14, 2024Beat
EPS Actual
-$5.28
EPS Est.
-$16.17
EPS Surpr.
+67.3%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $-10.08 | $-10.08 | $-10.08 | 1 |
| Q3 FY2025 | $-9.24 | $-9.24 | $-9.24 | 1 |
| Q4 FY2024 | $-2966.04 | $-2966.04 | $-2966.04 | 1 |
| Q3 FY2024 | $-452.76 | $-452.76 | $-452.76 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q2 FY2026 | May 15, 2026 | — | $6.79 | $6.60 | -2.80% |
| ▼ Q2 FY2026 | Apr 15, 2026 | -62.9% | $8.90 | $8.91 | +0.11% |
| ▲ Q4 FY2025 | Nov 14, 2025 | +40.6% | $8.42 | $9.24 | +9.74% |
| ▲ Q3 FY2025 | Aug 14, 2025 | +43.1% | $11.59 | $11.05 | -4.66% |
| ▼ Q2 FY2025 | May 14, 2025 | -423.7% | $9.72 | $9.71 | -0.10% |
| ▲ Q1 FY2025 | Mar 28, 2025 | +84.3% | $14.56 | $13.72 | -5.77% |
| ▲ Q4 FY2024 | Nov 14, 2024 | +67.3% | $235.48 | $226.52 | -3.80% |
| ▼ Q3 FY2024 | Aug 14, 2024 | -27.6% | $159.88 | $147.28 | -7.88% |
Q2 FY2026-2.80%
Report Date
May 15, 2026
EPS Beat/Miss
—
Price Before
$6.79
Price After
$6.60
Q2 FY2026+0.11%
Report Date
Apr 15, 2026
EPS Beat/Miss
-62.9%
Price Before
$8.90
Price After
$8.91
Q4 FY2025+9.74%
Report Date
Nov 14, 2025
EPS Beat/Miss
+40.6%
Price Before
$8.42
Price After
$9.24
Q3 FY2025-4.66%
Report Date
Aug 14, 2025
EPS Beat/Miss
+43.1%
Price Before
$11.59
Price After
$11.05
Q2 FY2025-0.10%
Report Date
May 14, 2025
EPS Beat/Miss
-423.7%
Price Before
$9.72
Price After
$9.71
Q1 FY2025-5.77%
Report Date
Mar 28, 2025
EPS Beat/Miss
+84.3%
Price Before
$14.56
Price After
$13.72
Q4 FY2024-3.80%
Report Date
Nov 14, 2024
EPS Beat/Miss
+67.3%
Price Before
$235.48
Price After
$226.52
Q3 FY2024-7.88%
Report Date
Aug 14, 2024
EPS Beat/Miss
-27.6%
Price Before
$159.88
Price After
$147.28
Avg Beat Reaction-1.12%
Avg Miss Reaction-2.62%
Beat Rate4 / 8 quarters
Largest Move+9.74% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: RNAZ ends December
TransCode Therapeutics, Inc. (RNAZ) most recently reported earnings on May 15, 2026 for Q2 FY2026, posting EPS of $-21.28 (in line with the analyst consensus of —). The next RNAZ earnings date is expected around September 1, 2026.
Each quarter, investors track RNAZ earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. RNAZ revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
RNAZ's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
RNAZ earnings · 4 questionsTransCode Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. RNAZ typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; RNAZ historically reports after market close (AMC).
RNAZ earnings datewhen is RNAZ earningsRNAZ next earnings datewhen does RNAZ report earningsRNAZ earnings calendar
▸ Source: FMP · TransCode Therapeutics, Inc. SEC filings · US GAAP · TransCode Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026